Optical Spectral Fingerprints of Tissues from Patients with Different Breast Cancer Histologies Using a Novel Fluorescence Spectroscopic Device

Laura A. Sordillo
Yang Pu, Ph.D.
Peter P. Sordillo, M.D., Ph.D.
Yury Budansky
R. R. Alfano, Ph.D.*

Institute for Ultrafast Spectroscopy and Lasers, Department of Physics, The City College of the City University of New York, 160 Convent Avenue, New York, NY 10031

The fluorescence of paired human breast malignant and normal tissue samples was investigated using a novel fluorescence spectroscopic (S³-LED) ratiometer unit with no moving parts. This device can measure the emission spectra of key native organic biomolecules such as tryptophan, tyrosine, collagen and elastin within tissues by using LED (light emitting diode) excitation sources coupled to an optical fiber. With this device, the spectral profiles of 11 paired breast cancerous and normal samples from 11 patients with breast carcinoma were obtained. In each of the 11 cases, marked increases in the tryptophan levels were found in the breast carcinoma samples when compared to the normal breast tissues. In the breast cancer samples, there were also consistently higher ratios of the 340 to 440 nm and the 340 to 460 nm intensity peaks after 280 nm excitation, likely representing an increased tryptophan to NADH ratio in the breast cancer samples. This difference was seen in the spectral profiles of the breast cancer patients regardless of whether they were HER2 positive or negative or hormone receptor positive or negative, and was found regardless of menopausal status, histology, stage, or tumor grade.

Key words: Breast carcinoma; Cancer detection; Fluorescence spectroscopy; Stokes shift; Optical fingerprint; Optical biopsy; Tryptophan; Compact medical explorer; Portable fluorescence device.

Introduction

In 1984, an alternative approach to cancer detection, known as fluorescence spectroscopy or autofluorescence spectroscopy, was introduced by Alfano et al. (1). This approach utilizes the emission of light from the native biomolecules present in tissues, without the use of extrinsic dyes. Because key organic biomolecules such as tryptophan, collagen, elastin and nicotinamide adenine dinucleotide (NADH) have absorption and emission peaks that occur at different wavelengths, an optical fingerprint of the studied tissue can be obtained. Analysis of these spectral peaks can give information about the changes that occur in cancer and other diseases. At about the same time, Profio et al. used fluorescence of lung tissues with extrinsic dyes during bronchoscopy to localize bronchogenic carcinoma (2). Soon after, Tata et al. studied fluorescence polarization spectroscopy of native cancerous and normal kidney tissues (3). The next major advance in optical spectroscopy occurred in 1987, when Alfano et al. investigated the fluorescence spectra from cancerous

Abbreviations: NADH: Nicotinamide Adenine Dinucleotide; S³: Stokes Shift Spectroscopy; LED: Light Emitting Diode; UV: Ultraviolet; LDA: Linear Discriminant Analysis; PCA: Principle Component Analysis; ROC: Receiver Operator Characteristic; AUC: Area Under the Curve.

*Corresponding author:
R. R. Alfano, Ph.D.
E-mail: ralfano@sci.ccny.cuny.edu
and normal human breast and lung tissues (4). For the next decade, other investigators utilized ultraviolet and visible light for cancer diagnosis, and key advances were made (5-11). For example, Svanberg et al. used laser-induced fluorescence for tissue characterization (7). Gupta et al. studied breast cancer diagnosis using N₂ laser excited native fluorescence spectroscopy (9) and Bigio et al. used scattering light spectroscopy for tissue diagnosis (10). Recently, many other investigators have also utilized light for cancer diagnosis (12-22). In 2007, Alimova et al. investigated hybrid phosphorescence and fluorescence native spectroscopy for breast cancer detection utilizing UV LED excitation (22).

The fluorescence of paired human breast malignant and normal tissue samples was investigated using a novel fluorescence spectroscopic ratiometer unit with no moving parts. The unit was tested on 22 samples from 11 breast cancer patients (11 pairs of normal and cancerous breast cancer tissues). In this work, we used native fluorescence spectroscopy with a selective excitation wavelength of 280 nm to study tissues from patients with different breast cancer histologies. Linear Discriminant Analysis (LDA) was applied to separate Principle Component Analysis (PCA)-analyzed results into two categories: cancer (malignant) and normal. To highlight the spectral difference between cancerous and normal breast tissues caused by key fluorophores, the ratios of intensities at 340 nm/440 nm and 340 nm/460 nm were calculated from the spectral peaks for both breast normal and malignant tissues.

Materials and Methods

S³-LED Ratiometer Unit

The S³-LED ratiometer unit (Figure 1) has multiple wavelength LEDs coupled to an optical fiber and wavelengths in the ultraviolet to blue-green range (280 nm-520 nm). The main parts of the S³-LED unit are shown in Figure 2. The unit contains a miniature fiber Ocean Optics spectrometer which consists of a linear silicon array detector and is equipped with an additional detection collection lens for increased light efficiency. The Ocean Optics spectrometer can collect light in the wavelength range of 200 to 1100 nm with a spectral resolution of ~33 nm and an acquisition time of less than 1 second. The LEDs are less than 1 mm squared and create enough power to excite a sample and to be detected by the sensitive Ocean Optics spectrometer. LEDs offer a higher efficiency and lifetime compared to lamp sources. This device is compact and no external power is needed.

Samples

The S³-LED ratiometer unit was used to obtain the fluorescence spectra to show differences in spectral peaks of key biomolecules in 11 paired breast normal and malignant tissue samples from patients with different breast cancer histologies. Fresh tissues of random shapes were supplied by the National Disease Research Interchange (NDRI) and the Cooperative Human Tissue Network (CHTN) under an Institutional Review Board (IRB) protocol. All tissue samples were measured within 24 hours of removal from the patient. The fresh breast normal and malignant samples from the same patient were measured at the same time. The patient ages ranged from 44 to 76 (see Table I). Eight were post-menopausal, two were pre-menopausal and one was perimenopausal. Nine were caucasian and two were black. All 11 patients had been treated with mastectomy. None of patients had received prior radiation to the breast. Two had received prior neo-adjuvant chemotherapy without shrinkage of tumor, while nine were treatment naive. Measurements were acquired from multiple random locations along the surfaces of the samples. Cuvettes were used to hold tissue samples. The wavelengths collected by the Ocean Optics spectrometer ranged from 300 nm to 700 nm. Photographs of paired malignant and normal breast tissues in a 1 cm × 1 cm × 5 cm quartz cuvette are shown in Figure 3A. A microscopic image of stained pathology slides (20X magnified) from malignant and normal tissues from patient 3 can also be seen in Figure 3B (image on the left is cancerous breast tissue sample).

Principal Component Analysis (PCA)

Principal Component Analysis (PCA) was used to analyze the 11 paired breast cancer samples. PCA is a mathematical procedure that uses an orthogonal transformation to convert a set of observations of possibly correlated variables into a set of values of linearly uncorrelated variables called principal components. In our study, PCA was applied as a technique that can resolve a complete spectral data set into a few principal components and can thus identify and isolate important trends within the data set. Therefore, PCA was used to reduce the number of parameters needed to represent the variance in the spectral data set. Subsequently, Linear Discriminant Analysis (LDA) was employed.
Linear Discriminant Analysis (LDA)

Linear Discriminant Analysis (LDA) is a method to find a linear combination of features which separates two or more classes of objects or events. This method is commonly useful for two group classes of significant discriminants. In our study, LDA was applied to separate the PCA-analyzed results into two categories: cancer (malignant) and normal. To evaluate the performance of the PCA algorithm combined with LDA for diagnosis of human breast cancer, the following terms can be used 1) true positive: a cancerous sample correctly diagnosed as malignant; 2) false positive: a healthy sample incorrectly identified as malignant; 3) true negative: a healthy sample correctly identified as healthy; and 4) false negative: a cancerous sample incorrectly identified as healthy. Sensitivity and specificity are then calculated. Sensitivity is the proportion of true negatives correctly recognized. Specificity is the proportion of true positives correctly identified. The sensitivity and specificity scores range between 0 and 1, where the larger the score the better the method.

Receiver Operator Characteristic (ROC)

A Receiver Operator Characteristic (ROC) curve is a graphical plot of two group classes; true positive rate (sensitivity) vs. false positive rate (1 minus specificity). Accuracy is measured by the area under the ROC curve (AUC). A rough guide for analyzing the accuracy of a diagnostic test is the standard academic point system: (A) excellent = 0.90-1; (B) good = 0.80-0.90; (C) fair = 0.70-0.80; (D) poor = 0.60-0.70; and (E) fail = 0.50-0.60.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age/Sex</th>
<th>Histology</th>
<th>Stage</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>76F</td>
<td>Invasive ductal carcinoma</td>
<td>2A</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>61F</td>
<td>Multifocal invasive ductal carcinoma</td>
<td>3C</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>74F</td>
<td>Invasive micropapillary breast carcinoma</td>
<td>3C</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>59F</td>
<td>Invasive ductal carcinoma</td>
<td>3C</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>44F</td>
<td>Invasive metaplastic carcinoma, matrix producing subtype with chondroid and squamous differentiation</td>
<td>3C</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>66F</td>
<td>Invasive ductal carcinoma</td>
<td>2A</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>54F</td>
<td>Invasive ductal carcinoma</td>
<td>3C</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>59F</td>
<td>Invasive ductal carcinoma</td>
<td>3A</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>66F</td>
<td>Invasive ductal carcinoma</td>
<td>3A</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>63F</td>
<td>Invasive ductal carcinoma</td>
<td>2B</td>
<td>3</td>
</tr>
<tr>
<td>11</td>
<td>48F</td>
<td>Invasive lobular carcinoma, pleomorphic variant</td>
<td>2A</td>
<td>2</td>
</tr>
</tbody>
</table>
Results

Fluorescence from Human Breast Tissues

The fluorescence spectra of the malignant and normal breast cancer samples from the 11 patients were notably different. The fluorescence intensities at 340 nm obtained with a 280 nm excitation source were stronger in the malignant samples than in the normal samples, while the intensities at 440 nm were stronger in the normal samples. The average fluorescence spectral profiles of cancerous (solid line) and normal (dashed line) breast tissue from the 11 patients with standard deviation error bars at key wavelengths are shown in Figure 4. The main peaks are found at 340 nm in both the malignant and normal samples with the peaks in the malignant samples higher. This is consistent with previous studies where we investigated biomolecules such as tryptophan, collagen, elastin, NADH, and other key fluorophores using absorption and fluorescence spectroscopy (1, 3-6).

To highlight the spectral difference between cancerous and normal breast tissues caused by key fluorophores, the ratios of intensities at 340 nm/440 nm and 340 nm/460 nm were calculated for both breast normal and malignant tissues from the spectral peaks. The ratios were consistently higher in the breast cancer samples compared to the normal samples, likely representing an increased tryptophan to NADH ratio in the breast cancer samples. A consistent difference in the 340 nm/440 nm and 340 nm/460 nm ratios was seen between malignant and normal breast cancer samples regardless of tumor histology, stage, grade, menopausal status or hormone receptor status. For example, this difference was seen for both patient 8 (Figure 5) and for patient 10 (Figure 6). It was noted that the difference was greater for patient 10 than for patient 8. The reason for this is unclear, but may have been because patient 10’s tumor was more malignant by several important measures. It was very large (4.8 cm compared 2.8 cm for patient 8’s tumor), was progesterone receptor negative while patient 8’s tumor was progesterone receptor positive, and had fewer estrogen receptors (more than 95% vs. 19%). As expected, the difference in 340 nm/440 nm and 340 nm/460 nm ratios between the benign and malignant breast tissue samples was also seen in the two patients who received neo-adjuvant chemotherapy without tumor shrinkage.
Statistical Classification

The data collected from 11 patients collected using the S3-LED ratiometer unit with a 280 nm excitation source were analyzed by statistical methods. PCA was done on 11 patient samples of different breast cancer histologies. The fluorescence spectra of the malignant and normal breast cancer samples show intensity peaks at 340 nm and 440 nm. Principle component one (PC1) and principle component two (PC2) represent the data set obtained from the fluorescence spectra peaks at 340 nm and 440 nm respectively. Results of PCA along with LDA for 11 patients can be seen in Figure 7.

Figure 8 shows a ROC curve of true positive rate (sensitivity) vs. false positive rate (1 minus specificity). The sensitivity and specificity were calculated as 0.80 and 0.78 respectively. AUC is 0.84 and suggests good accuracy.
Discussion

A new compact S\(^1\)-LED ratiometer unit which is portable and without moving parts is described which can be used to distinguish normal from malignant breast tissues. Distinct differences at 340 nm and at 440 nm were observed between normal and malignant breast tissue. Based on previous studies (1, 3-6), the fluorescence and absorption peaks of tryptophan, NADH, flavin and other fluorophores of interest are summarized in Table II. The peaks observed at 340 nm are most likely attributable to tryptophan. In each of the 11 patient samples in our study, there was a weaker spectral signature in normal tissue than in the malignant tissue sample at 340 nm. This may be due to increased protein synthesis and the increased utilization of the amino acid tryptophan that occurs in more rapidly dividing cancer cells. Tryptophan is an amino acid required for protein synthesis, accounting for the majority of protein fluorescence. Because of the higher cell density and uncontrollable cell division in cancerous breast cells, increased fluorescence of tryptophan should be expected. A second peak was observed at 440 nm and is most likely attributable to the biomolecule NADH. Further, the 340 nm/440 nm and 340 nm/460 nm ratios were consistently greater in the malignant samples compared to the normal samples. It is noteworthy that the difference in the 340 nm/440 nm ratios and the 340 nm/460 nm ratios between the malignant and normal samples was seen regardless of the pathologic characteristics of the breast samples studied, although there was a suggestion that in a more malignant tumor there might have been a more profound difference. With this device, we were able to use the differences at 340 nm and 440 nm to distinguish benign from malignant tissues.

This S\(^1\)-LED ratiometer unit provides a simple and effective way of showing intrinsic properties of human breast tissue. Breast carcinomas that are pre-menopausal can be thought to represent a different disease than breast carcinomas that develop in the post-menopausal population. Likewise, tumors that have hormone receptor or Her2Neu receptor positivity have a different natural history, prognosis and treatment responsiveness than those that are receptor negative. Despite these differences, all of the samples from these breast cancer patients had similar spectral profiles with our device.

Table II

<table>
<thead>
<tr>
<th>Molecules</th>
<th>Tyrosine</th>
<th>Tryptophan</th>
<th>Collagen</th>
<th>Elastin</th>
<th>NADH</th>
<th>Flavin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption (nm)</td>
<td>275</td>
<td>287</td>
<td>339</td>
<td>351</td>
<td>340</td>
<td>375</td>
</tr>
<tr>
<td>Emission (nm)</td>
<td>303</td>
<td>342</td>
<td>380</td>
<td>410</td>
<td>440-460</td>
<td>525</td>
</tr>
</tbody>
</table>

Conclusion

This study demonstrates how the S\(^1\)-LED ratiometer unit can be used to evaluate normal and abnormal breast tissue samples from patients with different breast cancer histologies. The data of this study shows that this ratiometer unit can effectively obtain the fluorescence of key native organic biomolecules in complex breast tissue samples with the use of optical fiber technology and multi-wavelength LEDs. A consistent difference in the 340 nm/440 nm and 340 nm/460 nm ratios was seen between malignant and normal breast cancer samples regardless of tumor histology, stage, grade, menopausal status or hormone receptor status. This difference was greater for patient 10 than for patient 8 and may have been because patient 10’s tumor was more malignant by several important measures. Further investigation into the fluorescence of paired normal and malignant samples from patients with different breast cancer histologies should be done. This study suggests that this device can be used in vitro for distinguishing cancerous from normal tissue and could be used as part of the evaluation for determining whether a cancer has been completely resected, thus reducing the need for second or repeat surgeries.

Conflict of Interest

The authors report no conflicts of interest.

Acknowledgements

Laura A. Sordillo is a recipient of the Kaylie Entrepreneurship Award from the Grove Engineering School at The City College of the City University of New York and of the CCNY-MSKCC Graduate Award from the CCNY-MSKCC Partnership for Cancer Research Program. Dr. Yang Pu acknowledges support from the U. S. Army Medical Research and Material Command (USAMRMC) grant of W81XWH-11-1-0335 (CUNY RF # 47204-00-01). The authors acknowledge CHTN and NDRI for providing tissue samples.

References

4. Alfano, R. R., Tang, G., Pradhan, A., Lam, W., Choy, D., Opher, E. Fluorescence spectra from cancerous and normal human breast and
Compact Fluorescence Spectroscopic Device


Received: May 23, 2012; Revised: September 4, 2012; Accepted: January 8, 2013